Journal Home > Volume 16 , Issue 2
Nano Research 2023, 16(2): 2991-3003 https://doi.org/10.1007/s12274-022-4877-4
Research Article | Issue | Published: 30 September 2022

Manganese-doped mesoporous polydopamine nanoagent for T1-T2 magnetic resonance imaging and tumor therapy

Show Author's Information Xiuqi Hou1,§,  Xi Yang1,§,  Yanwen Xu3,§,  Jiayin Lin1,  Fang Zhang2,  Xiaohui Duan2,  Sitong Liu1,  Jie Liu1,  Jun Shen2,  Xintao Shuai4( ),  Zhong Cao1( )
School of Biomedical Engineering, Sun Yat-sen University, Guangzhou 510006, China
Department of Radiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
Translational Medicine Institute, Shenzhen Second People’s Hospital, the First Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen 518035, China
Nanomedicine Research Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China

§ Xiuqi Hou, Xi Yang, and Yanwen Xu contributed equally to this work.

Keywords:
immunotherapy, magnetic resonance imaging, mesoporous polydopamine, T1-T2 dual-mode, NO gas therapy
Topics:
Magnetic resonance imaging
Cite this article:
Hou X, Yang X, Xu Y, et al. Manganese-doped mesoporous polydopamine nanoagent for T1-T2 magnetic resonance imaging and tumor therapy. Nano Research, 2023, 16(2): 2991-3003. https://doi.org/10.1007/s12274-022-4877-4
Download citation
EndNote(RIS)
BibTeX

651

Views

51

Downloads

Citations

10

Crossref

8

WoS

11

Scopus

0

CSCD

Abstract Full text Electronic supplementary material About this article

Theranostic nanodrugs combining magnetic resonance imaging (MRI) and cancer therapy have attracted extensive interest in cancer diagnosis and treatment. Herein, a manganese (Mn)-doped mesoporous polydopamine (Mn-MPDA) nanodrug incorporating the nitric oxide (NO) prodrug BNN6 and immune agonist R848 was developed. The nanodrug responded to the H+ and glutathione being enriched in tumor microenvironment to release R848 and Mn2+. The abundant Mn2+ produced through a Fenton-like reaction enabled a highly sensitive T1-T2 dual-mode MRI for monitoring the tumor accumulation process of the nanodrug, based on which an MRI-guided laser irradiation was achieved to trigger the NO gas therapy. Meanwhile, R848 induced the re-polarization of tumor-promoting M2-like macrophage to a tumoricidal M1 phenotype. Consequently, a potent synergistic antitumor effect was realized in mice bearing subcutaneous 4T1 breast cancer, which manifested the great promise of this multifunctional nanoplatform in cancer treatment.


menu
Abstract
Full text
Outline
Electronic supplementary material
About this article

Manganese-doped mesoporous polydopamine nanoagent for T1-T2 magnetic resonance imaging and tumor therapy

Show Author's information Xiuqi Hou1,§, Xi Yang1,§, Yanwen Xu3,§, Jiayin Lin1, Fang Zhang2, Xiaohui Duan2, Sitong Liu1, Jie Liu1, Jun Shen2, Xintao Shuai4( ), Zhong Cao1( )
School of Biomedical Engineering, Sun Yat-sen University, Guangzhou 510006, China
Department of Radiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
Translational Medicine Institute, Shenzhen Second People’s Hospital, the First Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen 518035, China
Nanomedicine Research Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China

§ Xiuqi Hou, Xi Yang, and Yanwen Xu contributed equally to this work.

Abstract

Theranostic nanodrugs combining magnetic resonance imaging (MRI) and cancer therapy have attracted extensive interest in cancer diagnosis and treatment. Herein, a manganese (Mn)-doped mesoporous polydopamine (Mn-MPDA) nanodrug incorporating the nitric oxide (NO) prodrug BNN6 and immune agonist R848 was developed. The nanodrug responded to the H+ and glutathione being enriched in tumor microenvironment to release R848 and Mn2+. The abundant Mn2+ produced through a Fenton-like reaction enabled a highly sensitive T1-T2 dual-mode MRI for monitoring the tumor accumulation process of the nanodrug, based on which an MRI-guided laser irradiation was achieved to trigger the NO gas therapy. Meanwhile, R848 induced the re-polarization of tumor-promoting M2-like macrophage to a tumoricidal M1 phenotype. Consequently, a potent synergistic antitumor effect was realized in mice bearing subcutaneous 4T1 breast cancer, which manifested the great promise of this multifunctional nanoplatform in cancer treatment.

Keywords: immunotherapy, magnetic resonance imaging, mesoporous polydopamine, T1-T2 dual-mode, NO gas therapy

References(36)

[1]

Zhou, Z. J.; Bai, R. L.; Munasinghe, J.; Shen, Z. Y.; Nie, L. M.; Chen, X. Y. T1-T2 dual-modal magnetic resonance imaging: From molecular basis to contrast agents. ACS Nano 2017, 11, 5227–5232.
DOI Google Scholar
[2]

Glunde, K.; Artemov, D.; Penet, M. F.; Jacobs, M. A.; Bhujwalla, Z. M. Magnetic resonance spectroscopy in metabolic and molecular imaging and diagnosis of cancer. Chem. Rev. 2010, 110, 3043–3059.
DOI Google Scholar
[3]

Zhou, Z. J.; Yang, L. J.; Gao, J. H.; Chen, X. Y. Structure–relaxivity relationships of magnetic nanoparticles for magnetic resonance imaging. Adv. Mater. 2019, 31, e1804567.
DOI Google Scholar
[4]

Yang, M. D.; Ho, C. H.; Ruta, S.; Chantrell, R.; Krycka, K.; Hovorka, O.; Chen, F. R.; Lai, P. S.; Lai, C. H. Magnetic interaction of multifunctional core–shell nanoparticles for highly effective theranostics. Adv. Mater. 2018, 30, e1802444.
DOI Google Scholar
[5]

Pablico-Lansigan, M. H.; Situ, S. F.; Samia, A. C. Magnetic particle imaging: Advancements and perspectives for real-time in vivo monitoring and image-guided therapy. Nanoscale 2013, 5, 4040–4055.
DOI Google Scholar
[6]

Zhou, Z. J.; Huang, D. T.; Bao, J. F.; Chen, Q. L.; Liu, G.; Chen, Z.; Chen, X. Y.; Gao, J. H. A synergistically enhanced T1-T2 dual-modal contrast agent. Adv. Mater. 2012, 24, 6223–6228.
DOI Google Scholar
[7]

Bhooshan, N.; Giger, M.; Lan, L.; Li, H.; Marquez, A.; Shimauchi, A.; Newstead, G. M. Combined use of T2-weighted MRI and T1-weighted dynamic contrast-enhanced MRI in the automated analysis of breast lesions. Magn. Reson. Med. 2011, 66, 555–564.
DOI Google Scholar
[8]

Gong, H.; Dong, Z. L.; Liu, Y. M.; Yin, S. N.; Cheng, L.; Xi, W. Y.; Xiang, J.; Liu, K.; Li, Y. G.; Liu, Z. Engineering of multifunctional nano-micelles for combined photothermal and photodynamic therapy under the guidance of multimodal imaging. Adv. Funct. Mater. 2014, 24, 6492–6502.
DOI Google Scholar
[9]

Krogsgaard, M.; Behrens, M. A.; Pedersen, J. S.; Birkedal, H. Self-healing mussel-inspired multi-pH-responsive hydrogels. Biomacromolecules 2013, 14, 297–301.
DOI Google Scholar
[10]

Guo, L. Q.; Liu, Q.; Li, G. L.; Shi, J. B.; Liu, J. Y.; Wang, T.; Jiang, G. B. A mussel-inspired polydopamine coating as a versatile platform for the in situ synthesis of graphene-based nanocomposites. Nanoscale 2012, 4, 5864–5867.
DOI Google Scholar
[11]

Wu, D.; Duan, X. H.; Guan, Q. Q.; Liu, J.; Yang, X.; Zhang, F.; Huang, P.; Shen, J.; Shuai, X. T.; Cao, Z. Mesoporous polydopamine carrying manganese carbonyl responds to tumor microenvironment for multimodal imaging-guided cancer therapy. Adv. Funct. Mater. 2019, 29, 1900095.
DOI Google Scholar
[12]

Chen, L. C.; Zhou, S. F.; Su, L. C.; Song, J. B. Gas-mediated cancer bioimaging and therapy. ACS Nano 2019, 13, 10887–10917.
DOI Google Scholar
[13]

Xu, W. M.; Liu, L. Z.; Loizidou, M.; Ahmed, M.; Charles, I. G. The role of nitric oxide in cancer. Cell Res. 2002, 12, 311–320.
DOI Google Scholar
[14]

Khan, F. H.; Dervan, E.; Bhattacharyya, D. D.; McAuliffe, J. D.; Miranda, K. M.; Glynn, S. A. The role of nitric oxide in cancer: Master regulator or not? Int. J. Mol. Sci. 2020, 21, 9393.
DOI Google Scholar
[15]

Xu, J. S.; Zeng, F.; Wu, H.; Hu, C. P.; Yu, C. M.; Wu, S. Z. Preparation of a mitochondria-targeted and no-releasing nanoplatform and its enhanced pro-apoptotic effect on cancer cells. Small 2014, 10, 3750–3760.
DOI Google Scholar
[16]

Lee, J.; Hlaing, S. P.; Hasan, N.; Kwak, D.; Kim, H.; Cao, J. F.; Yoon, I. S.; Yun, H.; Jung, Y.; Yoo, J. W. Tumor-penetrable nitric oxide-releasing nanoparticles potentiate local antimelanoma therapy. ACS Appl. Mater. Interfaces 2021, 13, 30383–30396.
DOI Google Scholar
[17]

Szabo, C. Gasotransmitters in cancer: From pathophysiology to experimental therapy. Nat. Rev. Drug Discov. 2016, 15, 185–203.
DOI Google Scholar
[18]

Dou, Y.; Zhao, F. S.; Li, X.; Guo, Y. Y. Monitoring nitric oxide-induced hypoxic tumor radiosensitization by radiation-activated nanoagents under BOLD/DWI imaging. ACS Biomater. Sci. Eng. 2021, 7, 5242–5254.
DOI Google Scholar
[19]

Paul, S.; Pan, S.; Mukherjee, A.; De, P. Nitric oxide releasing delivery platforms: Design, detection, biomedical applications, and future possibilities. Mol. Pharm. 2021, 18, 3181–3205.
DOI Google Scholar
[20]

Li, S. H.; Liu, R.; Jiang, X. X.; Qiu, Y.; Song, X. R.; Huang, G. M.; Fu, N. Y.; Lin, L. S.; Song, J. B.; Chen, X. Y. et al. Near-infrared light-triggered sulfur dioxide gas therapy of cancer. ACS Nano 2019, 13, 2103–2113.
DOI Google Scholar
[21]

He, Q. J. Precision gas therapy using intelligent nanomedicine. Biomater. Sci. 2017, 5, 2226–2230.
DOI Google Scholar
[22]

Fan, J.; He, N. Y.; He, Q. J.; Liu, Y.; Ma, Y.; Fu, X.; Liu, Y. J.; Huang, P.; Chen, X. Y. A novel self-assembled sandwich nanomedicine for NIR-responsive release of NO. Nanoscale 2015, 7, 20055–20062.
DOI Google Scholar
[23]

Deng, Y. Y.; Jia, F.; Chen, S. Y.; Shen, Z. D.; Jin, Q.; Fu, G. S.; Ji, J. Nitric oxide as an all-rounder for enhanced photodynamic therapy: Hypoxia relief, glutathione depletion and reactive nitrogen species generation. Biomaterials 2018, 187, 55–65.
DOI Google Scholar
[24]

Binnewies, M.; Roberts, E. W.; Kersten, K.; Chan, V.; Fearon, D. F.; Merad, M.; Coussens, L. M.; Gabrilovich, D. I.; Ostrand-Rosenberg, S.; Hedrick, C. C. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 2018, 24, 541–550.
DOI Google Scholar
[25]

Xiao, H.; Guo, Y.; Li, B.; Li, X. X.; Wang, Y.; Han, S. S.; Cheng, D.; Shuai, X. T. M2-like tumor-associated macrophage-targeted codelivery of STAT6 inhibitor and IKKβ siRNA induces M2-to-M1 repolarization for cancer immunotherapy with low immune side effects. ACS Cent. Sci. 2020, 6, 1208–1222.
DOI Google Scholar
[26]

Tang, X. Q.; Mo, C. F.; Wang, Y. S.; Wei, D. D.; Xiao, H. Y. Anti-tumour strategies aiming to target tumour-associated macrophages. Immunology 2013, 138, 93–104.
DOI Google Scholar
[27]

DeNardo, D. G.; Ruffell, B. Macrophages as regulators of tumour immunity and immunotherapy. Nat. Rev. Immunol. 2019, 19, 369–382.
DOI Google Scholar
[28]

Nadeem, A.; Siddiqui, N.; Al-Harbi, N. O.; Al-Harbi, M. M.; Ahmad, S. F. TLR-7 agonist attenuates airway reactivity and inflammation through Nrf2-mediated antioxidant protection in a murine model of allergic asthma. Int. J. Biochem. Cell Biol. 2016, 73, 53–62.
DOI Google Scholar
[29]

Hemmi, H.; Kaisho, T.; Takeuchi, O.; Sato, S.; Sanjo, H.; Hoshino, K.; Horiuchi, T.; Tomizawa, H.; Takeda, K.; Akira, S. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 2002, 3, 196–200.
DOI Google Scholar
[30]

Lee, M.; Park, C. S.; Lee, Y. R.; Im, S. A.; Song, S.; Lee, C. K. Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells. Arch. Pharm. Res. 2014, 37, 1234–1240.
DOI Google Scholar
[31]

Loré, K.; Betts, M. R.; Brenchley, J. M.; Kuruppu, J.; Khojasteh, S.; Perfetto, S.; Roederer, M.; Seder, R. A.; Koup, R. A. Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses. J. Immunol. 2003, 171, 4320–4328.
DOI Google Scholar
[32]

Wang, Y. K.; Liu, Y.; Wu, H. X.; Zhang, J. P.; Tian, Q. W.; Yang, S. P. Functionalized holmium-doped hollow silica nanospheres for combined sonodynamic and hypoxia-activated therapy. Adv. Funct. Mater. 2019, 29, 1805764.
DOI Google Scholar
[33]

Hao, Y. N.; Zheng, A. Q.; Guo, T. T.; Shu, Y.; Wang, J. H.; Johnson, O.; Chen, W. Glutathione triggered degradation of polydopamine to facilitate controlled drug release for synergic combinational cancer treatment. J. Mater. Chem. B 2019, 7, 6742–6750.
DOI Google Scholar
[34]

Ma, Z. W.; Xiang, X. Q.; Li, S. Y.; Xie, P.; Gong, Q.; Goh, B. C.; Wang, L. Z. Targeting hypoxia-inducible factor-1, for cancer treatment: Recent advances in developing small-molecule inhibitors from natural compounds. Semin. Cancer Biol. 2022, 80, 379–390.
DOI Google Scholar
[35]

Sung, Y. C.; Jin, P. R.; Chu, L. A.; Hsu, F. F.; Wang, M. R.; Chang, C. C.; Chiou, S. J.; Qiu, J. T.; Gao, D. Y.; Lin, C. C. et al. Delivery of nitric oxide with a nanocarrier promotes tumour vessel normalization and potentiates anti-cancer therapies. Nat. Nanotechnol. 2019, 14, 1160–1169.
DOI Google Scholar
[36]

Ridnour, L. A.; Isenberg, J. S.; Espey, M. G.; Thomas, D. D.; Roberts, D. D.; Wink, D. A. Nitric oxide regulates angiogenesis through a functional switch involving thrombospondin-1. Proc. Natl. Acad. Sci. USA 2005, 102, 13147–13152.
DOI Google Scholar
File
12274_2022_4877_MOESM1_ESM.pdf (1.6 MB)
Publication history
Copyright
Acknowledgements

Publication history

Received: 13 July 2022
Revised: 05 August 2022
Accepted: 06 August 2022
Published: 30 September 2022
Issue date: February 2023

Copyright

© Tsinghua University Press 2022

Acknowledgements

Acknowledgements

This work was supported by the National Natural Science Foundation of China (Nos. 51933011 and 31971296), the Key Areas Research and Development Program of Guangzhou (No. 202007020006), Guangdong Basic and Applied Basic Research Foundation (No. 2020A1515010523), Guangzhou Science and Technology Bureau (No. 202102010181), and Guangdong Provincial Key Laboratory of Sensing Technology and Biomedical Instrument (Sun Yat-sen University, No. 2020B1212060077).

The animal study protocol was approved by the Institutional Animal Care and Use Committee at Sun Yat-sen University (SYSU-IACUC-2021-000225).

Return